Wegovy Scripts Rise 7% While Foundayo Fetches 3,707 Prescriptions, Novo Teen Trial Succeeds
Novo Nordisk's Wegovy prescriptions rose 7% in the week ended April 17, while Eli Lilly’s oral Foundayo recorded only 3,707 versus Wegovy’s 18,410 prescriptions in its second week, extending Wegovy’s obesity-drug lead. Novo’s phase III teen trial of oral semaglutide achieved strong HbA1c reductions, paving way for first youth GLP-1 pill.
1. Prescription Data Comparison
Prescription data for the week ended April 17 show Novo Nordisk’s Wegovy prescriptions climbed 7% while Eli Lilly’s oral Foundayo logged only 3,707 scripts in its second week, widening the gap between the two leading obesity treatments.
2. Impact on Market Position
The uptake disparity underscores Wegovy’s entrenched market share and may temper investor expectations for rival launches, as newcomers face hurdles in matching established demand momentum despite similar therapeutic profiles.
3. Youth Trial Success
Novo Nordisk reported strong phase III results for oral semaglutide in adolescents, with significant HbA1c reductions and a favorable safety profile, positioning the company to introduce the first GLP-1 pill for youth pending regulatory approval.